The analysis suggests administration of Rebyota is associated with significant restoration of microbiota and bile acid composition.
Researchers say the findings suggest oversight of C diff patients by infectious disease specialists may result in better outcomes and resource management.
The treatment remained protective against recurrent C difficile infection in 86% of patients over a span of 2 years despite antibiotic exposure.
A longitudinal household study found shared C difficile strains in 17 of 28 families, with the infant detected first in most instances.
The CDC-developed strategy did not reduce incidence of hospital-onset C difficile over time at participating hospitals, but implementation was affected by COVID-19.
The American Gastroenterological Association says the document is the first comprehensive, evidence-based guideline on the use of FMT for recurrent C difficile.
Treatment with the narrow-spectrum investigational antibiotic ridinilazole resulted in a 53% relative reduction of recurrent C difficile infection compared with vancomycin.
In a population-based study, patients recently exposed to antibiotics and proton pump inhibitors had an 18-fold increase in the risk of C diff infection.
A study of two large, integrated health systems found a high incidence of outpatient CDI, despite limited testing of patients with diarrhea.
Researchers say new cleaning and disinfection methods that can better eradicate C difficile spores could help reduce the risk of healthcare transmission.
